These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 34396059)

  • 1. Identification of Novel Neutralizing Monoclonal Antibodies against SARS-CoV-2 Spike Glycoprotein.
    Bordoloi D; Xu Z; Ho M; Purwar M; Bhojnagarwala P; Cassel J; Giron LB; Walker S; Kulkarni AJ; Ruiz ET; Choi J; Zaidi FI; Wu Y; Wang S; Patel A; Ramos S; Smith T; Kulp D; Ugen KE; Srinivasan A; Abdel-Mohsen M; Humeau L; Weiner DB; Muthumani K
    ACS Pharmacol Transl Sci; 2021 Aug; 4(4):1349-1361. PubMed ID: 34396059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.
    Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R
    J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.
    Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA
    mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epitope mapping of severe acute respiratory syndrome coronavirus 2 neutralizing receptor binding domain-specific monoclonal antibodies.
    Maghsood F; Amiri MM; Zarnani AH; Salimi V; Kardar GA; Khoshnoodi J; Mobini M; Ahmadi Zare H; Ghaderi A; Jeddi-Tehrani M; Schmidt S; Laumond G; Moog C; Shokri F
    Front Med (Lausanne); 2022; 9():973036. PubMed ID: 36148457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian Hamsters.
    Su W; Sia SF; Schmitz AJ; Bricker TL; Starr TN; Greaney AJ; Turner JS; Mohammed BM; Liu Z; Choy KT; Darling TL; Joshi A; Cheng KM; Wong AYL; Harastani HH; Nicholls JM; Whelan SPJ; Bloom JD; Yen HL; Ellebedy AH; Boon ACM
    mBio; 2021 Oct; 12(5):e0239521. PubMed ID: 34517754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein structure analysis of the interactions between SARS-CoV-2 spike protein and the human ACE2 receptor: from conformational changes to novel neutralizing antibodies.
    Mercurio I; Tragni V; Busto F; De Grassi A; Pierri CL
    Cell Mol Life Sci; 2021 Feb; 78(4):1501-1522. PubMed ID: 32623480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of human anti-spike protein receptor binding domain antibodies on severe acute respiratory syndrome coronavirus neutralization escape and fitness.
    Sui J; Deming M; Rockx B; Liddington RC; Zhu QK; Baric RS; Marasco WA
    J Virol; 2014 Dec; 88(23):13769-80. PubMed ID: 25231316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Establishment of Neutralizing Monoclonal Antibodies Against Severe Acute Respiratory Syndrome Coronavirus 2 by the Screening with Exosomes Expressing the Viral Spike Protein.
    Okada C; Ikeda-Ishizaka E; Ono C; Matsuura Y; Sonoda H
    Monoclon Antib Immunodiagn Immunother; 2022 Aug; 41(4):173-180. PubMed ID: 36027043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies.
    Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B
    Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization.
    Shah M; Ahmad B; Choi S; Woo HG
    Comput Struct Biotechnol J; 2020; 18():3402-3414. PubMed ID: 33200028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A highly sensitive bead-based flow cytometric competitive binding assay to detect SARS-CoV-2 neutralizing antibody activity.
    Yao X; Zhang Z; Mei Q; Li S; Xing L; Long Y; Zhang D; Wang J; Wang X; Xie B; Yang B; Gao Y; Wu C; Meng Q
    Front Immunol; 2022; 13():1041860. PubMed ID: 36532082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
    He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
    Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RBD-Fc-based COVID-19 vaccine candidate induces highly potent SARS-CoV-2 neutralizing antibody response.
    Liu Z; Xu W; Xia S; Gu C; Wang X; Wang Q; Zhou J; Wu Y; Cai X; Qu D; Ying T; Xie Y; Lu L; Yuan Z; Jiang S
    Signal Transduct Target Ther; 2020 Nov; 5(1):282. PubMed ID: 33247109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single domain antibodies derived from ancient animals as broadly neutralizing agents for SARS-CoV-2 and other coronaviruses.
    Lim HT; Kok BH; Lim CP; Abdul Majeed AB; Leow CY; Leow CH
    Biomed Eng Adv; 2022 Dec; 4():100054. PubMed ID: 36158162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation.
    Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L
    Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
    Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
    Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.